Related Experiment Video

Updated: Dec 28, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.0K

News on the horizon in glioblastoma therapy

Ulrich Herrlinger1

  • 1Division of Clinical Neurooncology, Department of Neurology and Center of Integrated Oncology, University Hospital Bonn, Bonn, Germany ulrich.herrlinger@ukbonn.de.

ESMO Open
|February 15, 2020
PubMed

Abstract:

Click here to listen to the Podcast.

Keywords:
Podcast

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.0K

Related Experiment Videos

Last Updated: Dec 28, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.0K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

Articles linked to this work by shared authors, journal, and citation graph.

Lomustine with or without procarbazine in recurrent glioblastoma-A propensity score matching analysis.

Neuro-oncology advances·2026

Core2Edge: a human glioblastoma organoid-brain slice model capturing infiltration and transcriptional heterogeneity from core to single-cell dispersion.

Nature protocols·2026

Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial.

Nature cancer·2026

APTw CEST MRI in therapy-naive IDH-wildtype glioblastoma: insights into tumor heterogeneity and molecular subtypes.

Journal of neuro-oncology·2026

Proof of concept: Portable ultra-low-field MRI for the assessment of brain tumors.

Neuro-oncology practice·2026

Tumor genomic landscape of older patients with metastatic breast cancer☆.

ESMO open·2026

Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting.

ESMO open·2026

Insights into rhabdomyosarcoma in the adolescent and young adult population: a comprehensive clinical study from the French Society of Pediatric Oncology (SFCE) Malignant Mesenchymal Tumor (MMT) Committee and the French Sarcoma Group (GSF-GETO).

ESMO open·2026

Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort.

ESMO open·2026

Clinically actionable genomic alterations in breast cancer brain metastases.

ESMO open·2026

Multiregion profiling of genomic and transcriptional heterogeneity in head and neck squamous-cell carcinoma.

ESMO open·2026

Dynamic mode decomposition by tensor evolution for source depth.

The Journal of the Acoustical Society of America·2026

Understanding susceptibility to inattentional deafness in safety-critical environments.

Journal of safety research·2026

Hardware-efficient multiplier-free complex-valued shift-add neural network equalizer for 210-Gb/s 128-QAM SSB-DD links.

Optics letters·2026

Noise-Enhanced Hamming Code Transmission over an Additive Gaussian Mixture Noise Channel with One-Bit ADCs.

Sensors (Basel, Switzerland)·2026

Identifiability-Aware, Cost-Aware Triage of Physical Faults and Measurement-Integrity Anomalies in Energy Cyber-Physical Systems.

Sensors (Basel, Switzerland)·2026

Smartphone Acoustic Sensing for Contactless Respiration Monitoring and Gesture-Based Authentication.

Sensors (Basel, Switzerland)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us